Pain relief drug trial for mast cell syndrome stalls early

NCT ID NCT05652907

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested whether FSD201 tablets could reduce chronic pain in adults with mast cell activation syndrome. The study planned to enroll many participants but was terminated early with only 2 people. No results are available to show if the drug works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

FSD201 (tablets)

What this could lead to

If it worked, this could point toward a treatment for chronic pain in people with mast cell activation syndrome.

What could go wrong

The trial was terminated early with only 2 participants, so no reliable conclusions can be drawn. It is unclear if FSD201 is safe or effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAST CELL ACTIVATION SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic mast cell activation syndrome mast cell activation syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Norman Marcus Pain Institute

    New York, New York, 10016, United States

  • Saint Charles Clinical Research

    Weldon Spring, Missouri, 63304, United States

  • Toronto Rehabilitation Institute

    Toronto, Ontario, Canada